Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Sandoz Inc. v. Amgen Inc. et al
Case Number:
3:13-cv-02904
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
November 13, 2013
1st Biosimilars Act Ruling May Limit Patent Challenges
The ability of biosimilars makers to make early challenges to biologic drug patents may be curtailed by a Tuesday ruling throwing out Sandoz Inc.'s suit to invalidate patents for Amgen Inc.'s biologic arthritis drug Enbrel, the first time a judge has interpreted the litigation provisions of the Biosimilars Act.
-
June 26, 2013
Sandoz Fights Amgen Enbrel Patent
Amgen Inc. and Hoffman-La Roche Inc. were struck with a California federal lawsuit Tuesday from Sandoz Inc. that says a generic form of arthritis drug Enbrel is not infringing two patents and a delay in the patents' issuance renders them invalid.